Teva Pharmaceutical Industries Limited (TEVA)
Company Info
US8816242098
881624209
Mar 26, 1990
Highlights
$18.80B
-$1.45
1.29
$16.61B
$8.17B
$725.00M
$12.47 - $22.80
$22.38
2.66%
2.56
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Teva Pharmaceutical Industries Limited (TEVA) returned -23.19% year-to-date (YTD) and 5.81% over the past 12 months. Over the past 10 years, TEVA returned -11.34% annually, underperforming the S&P 500 benchmark at 10.45%.
TEVA
-23.19%
19.56%
-1.05%
5.81%
8.46%
-11.34%
^GSPC (Benchmark)
-3.77%
3.72%
-5.60%
8.55%
14.11%
10.45%
Monthly Returns
The table below presents the monthly returns of TEVA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025 | -19.56% | -7.16% | -6.62% | 0.91% | 9.16% | -23.19% | |||||||
2024 | 15.90% | 8.68% | 7.30% | -0.43% | 20.50% | -4.02% | 7.26% | 8.26% | -4.50% | 2.33% | -9.00% | 31.35% | 111.11% |
2023 | 15.57% | -5.98% | -10.70% | -1.36% | -17.53% | 4.58% | 11.55% | 16.19% | 4.51% | -15.88% | 14.45% | 6.31% | 14.47% |
2022 | 5.24% | -3.56% | 15.50% | -7.24% | 4.48% | -17.36% | 24.73% | -3.62% | -10.73% | 10.53% | -1.68% | 3.99% | 13.86% |
2021 | 22.07% | -8.66% | 7.25% | -7.28% | -2.80% | -4.81% | -2.53% | -2.38% | 3.40% | -10.27% | -5.61% | -2.91% | -16.99% |
2020 | 6.12% | 10.87% | -22.12% | 19.60% | 16.67% | -1.60% | -6.41% | -14.47% | -8.71% | -3.22% | 9.06% | 1.47% | -1.53% |
2019 | 28.73% | -15.21% | -6.83% | -2.93% | -43.17% | 6.71% | -14.08% | -12.99% | -0.29% | 18.46% | 27.85% | -5.95% | -36.45% |
2018 | 7.70% | -8.28% | -8.71% | 5.21% | 19.58% | 13.12% | -1.56% | -4.30% | -5.98% | -7.24% | 7.81% | -28.41% | -18.63% |
2017 | -7.78% | 5.76% | -8.37% | -1.59% | -11.78% | 20.71% | -3.16% | -50.44% | 10.97% | -21.59% | 8.06% | 27.87% | -45.96% |
2016 | -6.34% | -9.02% | -3.76% | 1.76% | -4.10% | -3.16% | 6.51% | -5.21% | -8.69% | -7.11% | -11.79% | -2.97% | -43.20% |
2015 | -1.13% | 0.89% | 9.26% | -3.02% | 0.03% | -1.66% | 16.79% | -6.22% | -12.34% | 4.84% | 6.94% | 4.31% | 16.71% |
2014 | 11.35% | 12.62% | 5.91% | -7.53% | 4.06% | 3.82% | 2.06% | -1.17% | 2.34% | 5.06% | 1.46% | 0.93% | 47.36% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of TEVA is 65, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Teva Pharmaceutical Industries Limited (TEVA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Teva Pharmaceutical Industries Limited provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Dividend | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.85 | $1.36 | $1.36 | $1.37 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 4.49% | 3.75% | 2.07% | 2.38% |
Monthly Dividends
The table displays the monthly dividend distributions for Teva Pharmaceutical Industries Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2020 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2019 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2018 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2017 | $0.00 | $0.34 | $0.00 | $0.00 | $0.00 | $0.34 | $0.00 | $0.09 | $0.00 | $0.00 | $0.09 | $0.00 | $0.85 |
2016 | $0.00 | $0.34 | $0.00 | $0.00 | $0.34 | $0.00 | $0.00 | $0.34 | $0.00 | $0.00 | $0.00 | $0.34 | $1.36 |
2015 | $0.00 | $0.34 | $0.00 | $0.00 | $0.34 | $0.00 | $0.00 | $0.34 | $0.00 | $0.00 | $0.34 | $0.00 | $1.36 |
2014 | $0.35 | $0.00 | $0.00 | $0.35 | $0.00 | $0.00 | $0.35 | $0.00 | $0.00 | $0.32 | $0.00 | $1.37 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Teva Pharmaceutical Industries Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Teva Pharmaceutical Industries Limited was 90.80%, occurring on Aug 15, 2019. The portfolio has not yet recovered.
The current Teva Pharmaceutical Industries Limited drawdown is 74.73%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-90.8% | Jul 28, 2015 | 1021 | Aug 15, 2019 | — | — | — |
-51.99% | Jun 23, 1997 | 265 | Jul 10, 1998 | 371 | Dec 29, 1999 | 636 |
-43.97% | Mar 24, 2010 | 381 | Sep 23, 2011 | 783 | Nov 4, 2014 | 1164 |
-36.47% | May 15, 1996 | 64 | Aug 14, 1996 | 95 | Dec 30, 1996 | 159 |
-36.18% | Feb 25, 1994 | 220 | Jan 10, 1995 | 66 | Apr 13, 1995 | 286 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Teva Pharmaceutical Industries Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Teva Pharmaceutical Industries Limited, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 1.1% positive surprise.
Valuation
The Valuation section provides an overview of how Teva Pharmaceutical Industries Limited is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for TEVA compared to other companies in the Drug Manufacturers - Specialty & Generic industry. TEVA currently has a PEG ratio of 1.3. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TEVA relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TEVA has a P/S ratio of 1.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TEVA in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TEVA has a P/B value of 3.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
TTM | |
---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |